BR112015010501A2 - composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada - Google Patents

composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada

Info

Publication number
BR112015010501A2
BR112015010501A2 BR112015010501A BR112015010501A BR112015010501A2 BR 112015010501 A2 BR112015010501 A2 BR 112015010501A2 BR 112015010501 A BR112015010501 A BR 112015010501A BR 112015010501 A BR112015010501 A BR 112015010501A BR 112015010501 A2 BR112015010501 A2 BR 112015010501A2
Authority
BR
Brazil
Prior art keywords
nanoparticles
freeze
patient
compound
treating cancer
Prior art date
Application number
BR112015010501A
Other languages
English (en)
Portuguese (pt)
Inventor
S Drager Anthony
Chen Jian
d brown Peter
R Patel Piyush
Y Labell Rachel
C Roemmele Renee
Mckean Robert
P Bakale Roger
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of BR112015010501A2 publication Critical patent/BR112015010501A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
BR112015010501A 2012-11-12 2013-11-12 composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada BR112015010501A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (1)

Publication Number Publication Date
BR112015010501A2 true BR112015010501A2 (pt) 2017-07-11

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010501A BR112015010501A2 (pt) 2012-11-12 2013-11-12 composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada

Country Status (17)

Country Link
US (7) US9452988B2 (https=)
EP (1) EP2917183A1 (https=)
JP (1) JP6262246B2 (https=)
KR (1) KR20150086308A (https=)
AR (1) AR093457A1 (https=)
AU (1) AU2013342015B2 (https=)
BR (1) BR112015010501A2 (https=)
CA (1) CA2890462A1 (https=)
CL (1) CL2015001246A1 (https=)
EA (1) EA029706B1 (https=)
HK (2) HK1212977A1 (https=)
IL (1) IL238662A (https=)
MX (1) MX2015005805A (https=)
PH (1) PH12015501024A1 (https=)
SG (1) SG11201503560TA (https=)
TW (1) TWI598341B (https=)
WO (1) WO2014075035A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
BR112015010501A2 (pt) 2012-11-12 2017-07-11 Ignyta Inc composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
US9598377B2 (en) 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
US11071789B2 (en) * 2016-07-13 2021-07-27 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1343494A4 (en) * 2000-12-01 2005-08-03 Enzon Inc PROMOTERS TETRAPARTATES
US20060165987A1 (en) * 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
US8486924B2 (en) 2007-11-28 2013-07-16 Celator Pharmaceuticals, Inc. Taxane delivery system
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
CA2738855A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
EP2346836B1 (en) 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
EP2367542B1 (en) * 2008-12-03 2014-01-01 Astellas Deutschland GmbH Oral dosage forms of bendamustine
US20130202693A1 (en) 2010-06-02 2013-08-08 Astellas Deutschland Gmbh Oral Dosage Forms of Bendamustine
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
US20130217888A1 (en) 2010-11-01 2013-08-22 Shailpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
DE102010055499A1 (de) 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica
ES2694757T3 (es) 2012-06-19 2018-12-27 Synbias Pharma Ag Derivados de bendamustina y compuestos relacionados, y uso médico de los mismos para el tratamiento del cáncer
JP2015525799A (ja) 2012-08-10 2015-09-07 ユニバーシティ・オブ・ノース・テキサス・ヘルス・サイエンス・センターＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ ターゲティングポリアミノ酸および脂肪酸のコンジュゲートを含む薬物送達ビークル
BR112015010501A2 (pt) * 2012-11-12 2017-07-11 Ignyta Inc composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada

Also Published As

Publication number Publication date
US9149464B2 (en) 2015-10-06
US9150517B2 (en) 2015-10-06
IL238662A (en) 2017-08-31
AU2013342015B2 (en) 2016-11-24
TWI598341B (zh) 2017-09-11
TW201439069A (zh) 2014-10-16
US20150246023A1 (en) 2015-09-03
CN105051016A (zh) 2015-11-11
EA029706B1 (ru) 2018-05-31
JP2015536996A (ja) 2015-12-24
EP2917183A1 (en) 2015-09-16
CA2890462A1 (en) 2014-05-15
US9913827B2 (en) 2018-03-13
US20180147186A1 (en) 2018-05-31
US9630926B2 (en) 2017-04-25
US20160016912A1 (en) 2016-01-21
IL238662A0 (en) 2015-06-30
SG11201503560TA (en) 2015-06-29
US20170182008A1 (en) 2017-06-29
CL2015001246A1 (es) 2016-01-15
US20150274675A1 (en) 2015-10-01
AU2013342015A1 (en) 2015-05-28
EA201590925A1 (ru) 2015-09-30
HK1215701A1 (zh) 2016-09-09
PH12015501024A1 (en) 2015-07-27
HK1212977A1 (zh) 2016-06-24
AR093457A1 (es) 2015-06-10
WO2014075035A1 (en) 2014-05-15
KR20150086308A (ko) 2015-07-27
US9452988B2 (en) 2016-09-27
JP6262246B2 (ja) 2018-01-17
US20150232427A1 (en) 2015-08-20
US20160289198A1 (en) 2016-10-06
MX2015005805A (es) 2016-04-15

Similar Documents

Publication Publication Date Title
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112015007061A2 (pt) composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BR112015004489A2 (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
RS67779B1 (sr) Farmaceutska kompozicija, postupci za lečenje i njihova primena
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BR112014032105A2 (pt) método para o tratamento de câncer
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
BR112013018679A2 (pt) agente para o tratamento da alopecia
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
SG11201504791VA (en) Pharmaceutical composition for treating headache, and preparation method thereof
BR112014031899A8 (pt) composto, composição farmacêutica, e, método para tratamento de um distúrbio
BR112013013469A2 (pt) cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral
BR112014015753A2 (pt) derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2540 DE 10-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.